JP2022525546A5 - - Google Patents
Info
- Publication number
- JP2022525546A5 JP2022525546A5 JP2021556509A JP2021556509A JP2022525546A5 JP 2022525546 A5 JP2022525546 A5 JP 2022525546A5 JP 2021556509 A JP2021556509 A JP 2021556509A JP 2021556509 A JP2021556509 A JP 2021556509A JP 2022525546 A5 JP2022525546 A5 JP 2022525546A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide sequence
- positions
- scap
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962820895P | 2019-03-20 | 2019-03-20 | |
| US62/820,895 | 2019-03-20 | ||
| PCT/US2020/023564 WO2020191163A1 (en) | 2019-03-20 | 2020-03-19 | Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525546A JP2022525546A (ja) | 2022-05-17 |
| JP2022525546A5 true JP2022525546A5 (enExample) | 2023-03-20 |
Family
ID=70285941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556509A Pending JP2022525546A (ja) | 2019-03-20 | 2020-03-19 | ステロール調節エレメント結合転写タンパク質切断活性化タンパク質（ｓｃａｐ）阻害剤による上昇した脂質レベルの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11331332B2 (enExample) |
| EP (1) | EP3942047A1 (enExample) |
| JP (1) | JP2022525546A (enExample) |
| CN (1) | CN113825839A (enExample) |
| CA (1) | CA3133002A1 (enExample) |
| WO (1) | WO2020191163A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117757790A (zh) * | 2022-11-17 | 2024-03-26 | 北京福元医药股份有限公司 | 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| AU670818B2 (en) | 1992-04-03 | 1996-08-01 | Cosmoferm B.V. | Selective N-acylation of amino alcohols |
| LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| FR2710337B1 (fr) | 1993-09-23 | 1995-12-08 | Gerard Coquerel | Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé. |
| US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| IL156550A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| US20080249040A1 (en) | 2001-05-18 | 2008-10-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of sterol regulatory element binding protein 1 (SREBP1) gene expression using short interfering nucleic acid (siNA) |
| US20050014177A1 (en) | 2003-05-19 | 2005-01-20 | Koustubh Ranade | Human sterol response element binding protein 1 (SREBP1) single nucleotide polymorphisms |
| WO2008036638A2 (en) | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of scap and therapeutic uses thereof |
| EP3265088A1 (en) * | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
| EP3387129A1 (en) * | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| EP3740573A1 (en) | 2018-01-18 | 2020-11-25 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting srebp1 |
-
2020
- 2020-03-19 JP JP2021556509A patent/JP2022525546A/ja active Pending
- 2020-03-19 CA CA3133002A patent/CA3133002A1/en active Pending
- 2020-03-19 US US16/823,832 patent/US11331332B2/en active Active
- 2020-03-19 EP EP20719003.4A patent/EP3942047A1/en active Pending
- 2020-03-19 WO PCT/US2020/023564 patent/WO2020191163A1/en not_active Ceased
- 2020-03-19 CN CN202080036542.8A patent/CN113825839A/zh active Pending
-
2022
- 2022-04-13 US US17/719,588 patent/US20220323483A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2846307C (en) | Method for diagnosing a neurodegenerative disease | |
| ES2453895T3 (es) | Células que expresan vitamina K epóxido reductasa y uso de las mismas | |
| Yang et al. | Mechanistic insights into the link between a polymorphism of the 3′ UTR of the SLC7A1 gene and hypertension | |
| CN101316935B (zh) | 一种用于诊断食道癌的芯片 | |
| JP2020527329A5 (enExample) | ||
| US20080280843A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
| EP2488662A2 (en) | Methods for diagnosing and treating a pathology associated with a synonymous mutation occuring within a gene of interest | |
| JP2022525545A5 (enExample) | ||
| US20200147118A1 (en) | Compositions and methods for detection, risk assessment and treatment of diabetes, obesity, and inflammation | |
| WO2016201438A1 (en) | New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders | |
| CA3133000A1 (en) | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors | |
| US20080050358A1 (en) | Identification of Snps Associated with Hyperlipidemia, Dyslipidemia and Defective Carbohydrate Metabolism | |
| CN102399870B (zh) | 一种确定食道癌病人生存预后的试剂 | |
| JP2007511474A5 (enExample) | ||
| JP2022515838A5 (enExample) | ||
| CN118541481A (zh) | 用分化簇109(cd109)抑制剂治疗骨矿物质密度降低的方法 | |
| Tjärnlund-Wolf et al. | Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue | |
| JP2022525456A5 (enExample) | ||
| JP2022544393A (ja) | マクロファージ刺激１受容体（ｍｓｔ１ｒ）バリアント及びその使用 | |
| WO2019043201A1 (en) | TRANSCRIPTION FACTOR ZNF471 USED AS THERAPEUTIC AGENT AND BIOMARKER | |
| JP4317376B2 (ja) | 糖尿病性腎症遺伝子の検出方法 | |
| JP2024508824A5 (enExample) | ||
| JP2024545873A (ja) | インテグリンサブユニットα１（ＩＴＧＡ１）阻害剤による肺の状態の治療 | |
| CN107604065B (zh) | 一种肝癌miRNA标记物 | |
| RU2021121850A (ru) | Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7) |